WHO ICTRP trial
Phase II Study of First-line Amrubicin in Elderly Patients with Extensive…
JPRN-UMIN000009548 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-UMIN000009548 |
|---|---|
| Public title | Phase II Study of First-line Amrubicin in Elderly Patients with Extensive Disease Small-Cell Lung Cancer (CJLSG1104) |
| Scientific title | Phase II Study of First-line Amrubicin in Elderly Patients with Extensive Disease Small-Cell Lung Cancer (CJLSG1104) - Phase II Study of First-line Amrubicin in Elderly Patients with Extensive Disease Small-Cell Lung Cancer (CJLSG1104) |
| Primary sponsor | Central Japan Lung Study Group |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase II |
| Countries | Japan |
| Conditions | Small-cell lung cancer |
| Interventions | Patients are treated with amrubicin 35 mg/m2 days 1-3 every 3 weeks. G-CSF are given for at least 4 days from day 8. |
| Registration date | Dec 17, 2012 |
| Target size | 29 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: